Media and Communications

News

NA

Saturday, April 19, 2014
Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE® Patent Due to the Potential for the Company to Recover Patent Infringement Damages

The Chief Justice Found That Teva Had Demonstrated “a Fair Prospect of Success on the Merits” JERUSALEM--(BUSINESS WIRE)--Apr. 19, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that while the Chief Justice of the United States found that Teva had demonstrated “a fair prospect of success on the merits” in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the “’808 patent”), he denied the Company’s application to stay t Read More »

Thursday, April 17, 2014
Teva Settles Patent Litigation with Pfizer on Celebrex®

JERUSALEM--(BUSINESS WIRE)--Apr. 17, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva’s generic version of Celebrex® (celecoxib) 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for all Read More »

Tuesday, April 15, 2014
Teva Announces Launch of Generic Lunesta® Tablets in the United States

JERUSALEM--(BUSINESS WIRE)--Apr. 15, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta® (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States. Lunesta® Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasi Read More »

Friday, April 11, 2014
Philadelphia Parkinson's Disease CommUNITY Rallied At Rocky Statue Launching New Public Awareness Campaign From The Parkinson's Unity Walk Organization And Teva

"CommUNITY: Carrying the PD Torch" Campaign Seeks to Empower and Provide Support for PD Patients FRAZER, Pa., April 11, 2014 /PRNewswire/ -- Teva Pharmaceuticals, makers of AZILECT® (rasagiline tablets) a once-daily treatment for Parkinson's disease (PD), and the Parkinson's Unity Walk (PUW) announces the launch of a public awareness campaign, "CommUNITY: Carrying the PD Torch," to support Parkinson's disease (PD) patients during Parkinson's Disease Awareness Month in April. The campaign aims to empower patients to set their goals and work to achieve them by uniting th Read More »

Tuesday, April 08, 2014
Teva Announces First Approval and Launch of Generic Lovaza® Capsules in the United States

JERUSALEM--(BUSINESS WIRE)--Apr. 8, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States. Teva believes it is first-to-file and thus far is the only Company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza® Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the United States, according to IMS data as of December 2013. Read More »

Monday, March 10, 2014
Teva Pharmaceuticals and Volunteers in Medicine Partner to Expand Access to Healthcare in the U.S.

NORTH WALES, Pa. & BURLINGTON, Vt.--(BUSINESS WIRE)--Mar. 10, 2014-- Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Volunteers in Medicine (VIM), a national nonprofit organization dedicated to helping communities provide free primary healthcare clinics for families and individuals, today announced their 2014 National Partnership to make healthcare services more readily available to the uninsured. Currently, there are 96 VIM clinics in 29 states, providing free general primary Read More »

Friday, March 07, 2014
Teva Announces Launch of Generic Xeloda® Tablets 150 MG and 500 MG in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 7, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda® (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda® is marketed by Genentech in the United States. Teva was the first to receive approval on its ANDA from the U.S. Food and Drug Administration on September 16, 2013 and is launching today per a settlement agreement. Xeloda® (Capecitabine) Tablets, 150 MG and 500 MG had annual sales of approximately $754 millio Read More »

Tuesday, March 04, 2014
Teva Announces Approval of Generic Evista® Tablets 60 mg in the United States

JERUSALEM--(BUSINESS WIRE)--Mar. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval of the generic equivalent to Evista® (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Teva will begin shipping the product within the next 30 days. Evista® 60 mg Tablets marketed by Eli Lilly and Company, had annual sales of approximately $824 million in the United States, according to IMS data as of December 2013. Read More »

Monday, March 03, 2014
Teva Launches ADASUVE® in U.S.

The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults JERUSALEM--(BUSINESS WIRE)--Mar. 3, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE® (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE® is administered through Alexza Pharmaceuticals' Read More »

Friday, February 28, 2014
Teva to Present at the Cowen & Company 34th Annual Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Feb. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Cowen & Company 34th Annual Healthcare Conference in Boston, MA. Eyal Desheh, EVP & CFO will present on Tuesday, March 4, 2014 at 11:20 AM EST What:   Teva Presentation at the Cowen & Company 34th Annual Healthcare Conference Read More »

​​​